Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD5 | Q86SK9 | 5/20 | 0.53 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | PROKR1 | Q8TCW9 | 3/20 | 0.42 |
| ▸ | PDE2A | O00408 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4295123 | 0.92 | HSD17B14 (0.50) | SCD5HSD17B14SCD | |
| SCHEMBL4301946 | 0.83 | PROKR1 (0.51) | HSD17B14KMT2AALDH1A1LMNARAB9A | |
| SCHEMBL4303696 | 0.83 | HRH3 (0.49) | HSD17B14KMT2A | |
| SCHEMBL4303705 | 0.83 | HRH3 (0.49) | HSD17B14KMT2A | |
| SCHEMBL4293252 | 0.81 | HRH3 (0.51) | HSD17B14KMT2A | |
| SCHEMBL4293254 | 0.81 | HRH3 (0.51) | HSD17B14KMT2A | |
| SCHEMBL4290842 | 0.81 | HSD17B14 (0.46) | SCD5HSD17B14PROKR1SCD | |
| SCHEMBL4298105 | 0.80 | RIPK1 (0.51) | SCD5HSD17B14LMNA | |
| SCHEMBL4298114 | 0.80 | RIPK1 (0.51) | SCD5HSD17B14LMNA | |
| SCHEMBL4304173 | 0.78 | HSD17B14 (0.47) | HSD17B14KMT2ARAB9APROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | PFIZER INC. | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197859-A1 | Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders | HTR6, HTR5A, TPH1 | SCD5 1916/4885HSD17B14 2214/4885KMT2A 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.